Procalcitonin (PCT) has been used to evaluate the risk of progression to sepsis and septic shock in critically ill patients and 28-day mortality risk after diagnosis. Now the Elecsys® BRAHMS PCT assay may be used to support antibiotic treatment decisions in patients with suspected or confirmed lower respiratory tract infections (LRTI), defined as acute exacerbations of chronic obstructive pulmonary disease (aeCOPD), community-acquired pneumonia (CAP) and acute bronchitis, and aid in antibiotic discontinuation in patients with suspected or confirmed sepsis.
Today, fighting infections and managing antibiotic use go hand in hand. By adding procalcitonin (PCT) testing to lab and treatment protocols, healthcare systems could improve patient outcomes and potentially reduce the costs of care for certain bacterial infections and sepsis while curtailing unnecessary antibiotic use.1
Expanding hospital outreach serves the community — and the bottom line
See how one hospital increased laboratory annual billables and reduced costs, enabling it to expand services for the community.